Transcranial magnetic stimulation and amyotrophic lateral sclerosis: Pathophysiological insights

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 84, Issue 10, 2013, Pages 1161-1170

  Vucic, Steve ^a,b   Ziemann, Ulf ^c   Eisen, Andrew ^d   Hallett, Mark ^e   Kiernan, Matthew C ^b,f  

^a UNIVERSITY OF SYDNEY   (Australia)

^b NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR; AMPA RECEPTOR; BIOLOGICAL MARKER; CALCIUM ION; DEXPRAMIPEXOLE; EXCITATORY AMINO ACID TRANSPORTER 2; GLUTAMATE TRANSPORTER; RILUZOLE; SODIUM ION;

AMYOTROPHIC LATERAL SCLEROSIS; DIAGNOSTIC VALUE; DISEASE COURSE; ELECTROENCEPHALOGRAM; ENZYME ACTIVITY; EVOKED MUSCLE RESPONSE; HISTOGRAM; HUMAN; INTRACORTICAL FACILITATION; MUSCLE ACTION POTENTIAL; NERVE EXCITABILITY; NERVE STIMULATION; NERVOUS SYSTEM PARAMETERS; NEUROTRANSMISSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SHORT INTERVAL INTRACORTICAL INHIBITION; TRANSCRANIAL MAGNETIC STIMULATION; TRIPLE STIMULATION TECHNIQUE;

EID: 84880383482     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2012-304019     Document Type: Review

References (198)

1. Charcot J, Joffroy A. Deux cas d'atrophie musculaire progressive avec lesion de la substance grise et des faisceaux antero-lateraux de la moelle epiniere. Arch Physiol Neurol Pathol 1869; 2: 744-54.
2. Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet 2011; 377: 942-55.
3. Vucic S, Burke D, Kiernan MC. Diagnosis of motor neuron disease. In: Kiernan MC. ed. The motor neuron disease handbook. Sydney: Australasian Medical Publishing Company Limited, 2007: 89-115.
4. Winhammar JM, Rowe DB, Henderson RD, et al. Assessment of disease progression in motor neuron disease. Lancet Neurology 2005; 4: 229-38. (Pubitemid 40381110)
5. Ravits J, Paul P, Jorg C. Focality of upper and lower motor neuron degeneration at the clinical onset of ALS. Neurology 2007; 68: 1571-5. (Pubitemid 46717980)
6. Rossini PM, Berardelli A, Deuschl G, et al. Applications of magnetic cortical stimulation. The International Federation of Clinical Neurophysiology. Electroencephalogr Clin Neurophysiol Suppl 1999; 52: 171-85.
7. Fisher RJ, Nakamura Y, Bestmann S, et al. Two phases of intracortical inhibition revealed by transcranial magnetic threshold tracking. Exp Brain Res 2002; 143: 240-8. (Pubitemid 34212260)
8. Vucic S, Howells J, Trevillion L, et al. Assessment of cortical excitability using threshold tracking techniques. Muscle Nerve 2006; 33: 477-86.
9. Groppa S, Oliviero A, Eisen A, et al. A practical guide to diagnostic transcranial magnetic stimulation: report of an IFCN committee. Clin Neurophysiol 2012; 123: 858-82.
10. Brouwer B, Ashby P. Corticospinal projections to upper and lower limb spinal motoneurons in man. Electroencephalogr Clin Neurophysiol 1990; 76: 509-19.
11. Chen R, Tam A, Butefisch C, et al. Intracortical inhibition and facilitation in different representations of the human motor cortex. J Neurophysiol 1998; 80: 2870-81. (Pubitemid 29029219)
12. Macdonell RA, Shapiro BE, Chiappa KH, et al. Hemispheric threshold differences for motor evoked potentials produced by magnetic coil stimulation. Neurology 1991; 41: 1441-4.
13. Triggs WJ, Calvanio R, Levine M. Transcranial magnetic stimulation reveals a hemispheric asymmetry correlate of intermanual differences in motor performance. Neuropsychologia 1997; 35: 1355-63. (Pubitemid 27455562)
14. Amassian VE, Stewart M, Quirk GJ, et al. Physiological basis of motor effects of a transient stimulus to cerebral cortex. Neurosurgery 1987; 20: 74-93.
15. Epstein CM, Schwartzberg DG, Davey KR, et al. Localizing the site of magnetic brain stimulation in humans. Neurology 1990; 40: 666-70. (Pubitemid 20139098)
16. Rudiak D, Marg E. Finding the depth of magnetic brain stimulation: a re-evaluation. Electroencephalogr Clin Neurophysiol 1994; 93: 358-71. (Pubitemid 24314984)
17. Di Lazzaro V, Oliviero A, Profice P, et al. Ketamine increases human motor cortex excitability to transcranial magnetic stimulation. Journal of Physiology 2003; 547: 485-96. (Pubitemid 36304982)
18. Ziemann U. TMS and drugs. Clin Neurophysiol 2004; 115: 1717-29. (Pubitemid 38952939)
19. Attarian S, Azulay JP, Lardillier D, et al. Transcranial magnetic stimulation in lower motor neuron diseases. Clin Neurophysiol 2005; 116: 35-42. (Pubitemid 40267638)
20. Berardelli A, Inghilleri M, Cruccu G, et al. Electrical and magnetic transcranial stimulation in patients with corticospinal damage due to stroke or motor neurone disease. Electroencephalogr Clin Neurophysiol 1991; 81: 389-96.
21. Eisen A, Shytbel W, Murphy K, et al. Cortical magnetic stimulation in amyotrophic lateral sclerosis. Muscle Nerve 1990; 13: 146-51. (Pubitemid 20049330)
22. de Carvalho M, Turkman A, Swash M. Motor responses evoked by transcranial magnetic stimulation and peripheral nerve stimulation in the ulnar innervation in amyotrophic lateral sclerosis: the effect of upper and lower motor neuron lesion. J Neurol Sci 2003; 210: 83-90. (Pubitemid 36539410)
23. Miscio G, Pisano F, Mora G, et al. Motor neuron disease: usefulness of transcranial magnetic stimulation in improving the diagnosis. Clin Neurophysiol 1999; 110: 975-81. (Pubitemid 29281700)
24. Triggs WJ, Macdonell RA, Cros D, et al. Motor inhibition and excitation are independent effects of magnetic cortical stimulation. Annals of Neurol 1992; 32: 345-51.
25. Triggs WJ, Menkes D, Onorato J, et al. Transcranial magnetic stimulation identifies upper motor neuron involvement in motor neuron disease. Neurology 1999; 53: 605-11. (Pubitemid 29382058)
26. Urban P, Wicht S, Hopf H. Sensitivity of transcranial magnetic stimulation of cortico-bulbar vs. cortico-spinal tract involvement in ALS. J Neurol 2001; 248: 850-5. (Pubitemid 32958580)
27. Caramia MD, Cicinelli P, Paradiso C, et al. 'Excitability changes of muscular responses to magnetic brain stimulation in patients with central motor disorders. Electroencephalogr Clin Neurophysiol 1991; 81: 243-50.
28. Kohara N, Kaji R, Kojima Y, et al. Abnormal excitability of the corticospinal pathway in patients with amyotrophic lateral sclerosis: a single motor unit study using transcranial magnetic stimulation. Electroencephalogr Clin Neurophysiol 1996; 101: 32-41.
29. Mills KR, Nithi KA. Corticomotor threshold is reduced in early sporadic amyotrophic lateral sclerosis. Muscle Nerve 1997; 20: 1137-41. (Pubitemid 27352096)
30. Vucic S, Kiernan MC. Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain 2006; 129: 2436-46. (Pubitemid 44522128)
31. Vucic S, Nicholson GA, Kiernan MC. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain 2008; 131: 1540-50. (Pubitemid 351806458)
32. Zanette G, Tamburin S, Manganotti P, et al. Different mechanisms contribute to motor cortex hyperexcitability in amyotrophic lateral sclerosis. Clin Neurophysiol 2002; 113: 1688-97. (Pubitemid 35335457)
33. Eisen A, Weber M. The motor cortex and amyotrophic lateral sclerosis. Muscle Nerve 2001; 24: 564-73. (Pubitemid 32246795)
34. Hirota N, Eisen A, Weber M. Complex fasciculations and their origin in amyotrophic lateral sclerosis and Kennedy's disease. Muscle Nerve 2000; 23: 1872-5.
35. Di Lazzaro V, Restuccia D, Oliviero A, et al. Magnetic transcranial stimulation at intensities below active motor threshold activates intracortical inhibitory circuits. Exp Brain Res 1998; 119: 265-8. (Pubitemid 28098520)
36. Devanne H, Lavoie BA, Capaday C. Input-output properties and gain changes in the human corticospinal pathway. Exp Brain Res 1997; 114: 329-38. (Pubitemid 27187106)
37. Ziemann U. Cortical threshold and excitability measurements. In: Eisen A. ed. Clinical neurophysiology of motor neuron diseases handbook of clinical neurophysiology. Amsterdam: Elsevier, 2004: 317-35.
38. Chen R, Cros D, Curra A, et al. The clinical diagnostic utility of transcranial magnetic stimulation: report of an IFCN committee. Clin Neurophysiol 2008; 119: 504-32.
39. Hess CW, Mills KR, Murray NM, et al. Magnetic brain stimulation: central motor conduction studies in multiple sclerosis. Ann Neurol 1987; 22: 744-52. (Pubitemid 18018471)
40. Paulus W, Classen J, Cohen LG, et al. State of the art: pharmacologic effects on cortical excitability measures tested by transcranial magnetic stimulation. Brain Stimul 2008; 1: 151-63.
41. Boroojerdi B, Battaglia F, Muellbacher W, et al. Mechanisms influencing stimulus-response properties of the human corticospinal system. Clin Neurophysiol 2001; 112: 931-7. (Pubitemid 32406270)
42. Vucic S, Kiernan MC. Abnormalities in cortical and peripheral excitability in flail arm variant amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2007; 78: 849-52. (Pubitemid 47204591)
43. Vucic S, Kiernan MC. Upregulation of persistent sodium conductances in familial ALS. J Neurol Neurosurg Psychiatry 2010; 81: 222-7.
44. Vucic S, Kiernan MC. Cortical excitability testing distinguishes Kennedy's disease from amyotrophic lateral sclerosis. Clin Neurophysiol 2008; 119: 1088-96.
45. Vucic S, Cheah BC, Yiannikas C, et al. Corticomotoneuronal function and hyperexcitability in acquired neuromyotonia. Brain 2010; 133: 2727-33.
46. Vucic S, Nicholson GA, Kiernan MC. Cortical excitability in hereditary motor neuronopathy with pyramidal signs: comparison with ALS. J Neurol Neurosurg Psychiatry 2010; 81: 97-100.
47. Vucic S, Cheah BC, Yiannikas C, et al. Cortical excitability distinguishes ALS from mimic disorders. Clin Neurophysiol 2011; 122: 1860-6.
48. Mills K. Magnetic stimulation and central conduction time. In: Eisen A. ed. Clinical neurophysiology of motor neuron diseases handbook of clinical neurophysiology. Amsterdam: Elsevier, 2004: 283-93.
49. Claus D. Central motor conduction: method and normal results. Muscle Nerve 1990; 13: 1125-32.
50. Mills KR, Murray NM. Electrical stimulation over the human vertebral column: which neural elements are excited? Electroencephalogr Clin Neurophysiol 1986; 63: 582-9. (Pubitemid 16091365)
51. Rossini PM, Barker AT, Berardelli A, et al. Non-invasive electrical and magnetic stimulation of the brain, spinal cord and roots: basic principles and procedures for routine clinical application. Report of an IFCN committee. Electroencephalogr Clin Neurophysiol 1994; 91: 79-92. (Pubitemid 24246462)
52. Mills KR. The natural history of central motor abnormalities in amyotrophic lateral sclerosis. Brain 2003; 126: 2558-66. (Pubitemid 37314443)
53. Eisen A, Entezari-Taher M, Stewart H. Cortical projections to spinal motoneurons: changes with aging and amyotrophic lateral sclerosis. Neurology 1996; 46: 1396-404. (Pubitemid 26159304)
54. Komissarow L, Rollnik JD, Bogdanova D, et al. Triple stimulation technique (TST) in amyotrophic lateral sclerosis. Clin Neurophysiol 2004; 115: 356-60. (Pubitemid 38117256)
55. Turner MR, Osei-Lah AD, Hammers A, et al. Abnormal cortical excitability in sporadic but not homozygous D90A SOD1 ALS. J Neurol Neurosurg Psychiatry 2005; 76: 1279-85. (Pubitemid 41208385)
56. Mills K. Magnetic stimulation and central conduction time. Amsterdam: Elsevier B. V., 2004.
57. Cantello R, Gianelli M, Civardi C, et al. Magnetic brain stimulation: the silent period after the motor evoked potential. Neurology 1992; 42: 1951-9.
58. Inghilleri M, Berardelli A, Cruccu G, et al. Silent period evoked by transcranial stimulation of the human cortex and cervicomedullary junction. J Physiol (Lond) 1993; 466: 521-34. (Pubitemid 23225241)
59. Triggs WJ, Kiers L, Cros D, et al. Facilitation of magnetic motor evoked potentials during the cortical stimulation silent period. Neurology 1993; 43: 2615-20. (Pubitemid 24004555)
60. Chen R, Lozano AM, Ashby P. Mechanism of the silent period following transcranial magnetic stimulation. Evidence from epidural recordings. Exp Brain Res 1999; 128: 539-42. (Pubitemid 29469179)
61. Siebner HR, Dressnandt J, Auer C, et al. Continuous intrathecal baclofen infusions induced a marked increase of the transcranially evoked silent period in a patient with generalized dystonia. Muscle Nerve 1998; 21: 1209-12. (Pubitemid 28355572)
62. Werhahn KJ, Kunesch E, Noachtar S, et al. Differential effects on motorcortical inhibition induced by blockade of GABA uptake in humans. J Physiol (Lond) 1999; 517: 591-7. (Pubitemid 29296371)
63. Stetkarova I, Kofler M. Differential effects of cortical and spinal inhibitory circuits. Clin Neurophysiol 2013; 124: 339-45.
64. Desiato MT, Caramia MD. Towards a neurophysiological marker of amyotrophic lateral sclerosis as revealed by changes in cortical excitability. Electroencephalogr Clin Neurophysiol 1997; 105: 1-7. (Pubitemid 27157771)
65. Prout AJ, Eisen A. The cortical silent period and ALS. Muscle Nerve 1994; 17: 217-23.
66. Siciliano G, Manca ML, Sagliocco L, et al. Cortical silent period in patients with amyotrophic lateral sclerosis. J Neurol Sci 1999; 169: 93-7. (Pubitemid 29502514)
67. Wittstock M, Wolters A, Benecke R. Transcallosal inhibition in amyotrophic lateral sclerosis. Clin Neurophysiol 2007; 118: 301-7. (Pubitemid 46038807)
68. Wittstock M, Meister S, Walter U, et al. Mirror movements in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2011; 12: 393-7.
69. Meyer BU, Roricht S, Grafin von Einsiedel H, et al. Inhibitory and excitatory interhemispheric transfers between motor cortical areas in normal humans and patients with abnormalities of the corpus callosum. Brain 1995; 118: 429-40.
70. Kujirai T, Caramia MD, Rothwell JC, et al. Corticocortical inhibition in human motor cortex. J Physiol (Lond) 1993; 471: 501-19. (Pubitemid 23345592)
71. Hanajima R, Ugawa Y, Terao Y, et al. Paired-pulse magnetic stimulation of the human motor cortex: differences among I waves. J Physiol (Lond) 1998; 509: 607-18. (Pubitemid 28287017)
72. Nakamura H, Kitagawa H, Kawaguchi Y, et al. Intracortical facilitation and inhibition after transcranial magnetic stimulation in conscious humans. J Physiol (Lond) 1997; 498: 817-23. (Pubitemid 27089476)
73. Ziemann U, Rothwell JC, Ridding MC. Interaction between intracortical inhibition and facilitation in human motor cortex. J Physiol (Lond) 1996; 496: 873-81. (Pubitemid 26387868)
74. Di Lazzaro V, Oliviero A, Meglio M, et al. Direct demonstration of the effect of lorazepam on the excitability of the human motor cortex. Clin Neurophysiol 2000; 111: 794-9. (Pubitemid 30236423)
75. Kiers L, Cros D, Chiappa KH, et al. Variability of motor potentials evoked by transcranial magnetic stimulation. Electroencephalogr Clin Neurophysiol 1993; 89: 415-23. (Pubitemid 24024443)
76. Vucic S, Cheah BC, Krishnan AV, et al. The effects of alterations in conditioning stimulus intensity on short interval intracortical inhibition. Brain Res 2009; 1273: 39-47.
77. Vucic S, Cheah BC, Kiernan MC. Dissecting the Mechanisms Underlying Short-Interval Intracortical Inhibition Using Exercise. Cereb Cortex 2011: 1639-44.
78. Ziemann U, Lonnecker S, Steinhoff BJ, et al. The effect of lorazepam on the motor cortical excitability in man. Exp Brain Res 1996; 109: 127-35. (Pubitemid 26119972)
79. Ilic TV, Meintzschel F, Cleff U, et al. Short-interval paired-pulse inhibition and facilitation of human motor cortex: the dimension of stimulus intensity. J Physiol (Lond) 2002; 545: 153-67. (Pubitemid 35386133)
80. Di Lazzaro V, Pilato F, Dileone M, et al. GABAA receptor subtype specific enhancement of inhibition in human motor cortex. J Physiol 2006; 575: 721-6. (Pubitemid 44323738)
81. Hanajima R, Furubayashi T, Iwata NK, et al. Further evidence to support different mechanisms underlying intracortical inhibition of the motor cortex. Exp Brain Res 2003; 151: 427-34. (Pubitemid 36995142)
82. Roshan L, Paradiso GO, Chen R. Two phases of short-interval intracortical inhibition. Exp Brain Res 2003; 151: 330-7. (Pubitemid 36920896)
83. Hanajima R, Ugawa Y, Terao Y, et al. Ipsilateral cortico-cortical inhibition of the motor cortex in various neurological disorders. J Neurol Sci 1996; 114: 109-16. (Pubitemid 26273627)
84. Yokota T, Yoshino A, Inaba A, et al. Double cortical stimulation in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1996; 61: 596-600. (Pubitemid 27023337)
85. Ziemann U, Winter M, Reimers CD, et al. Impaired motor cortex inhibition in patients with amyotrophic lateral sclerosis. Evidence from paired transcranial magnetic stimulation. Neurology 1997; 49: 1292-8. (Pubitemid 27495632)
86. Sommer M, Tergau F, Wischer S, et al. Riluzole does not have an acute effect on motor thresholds and the intracortical excitability in amyotrophic lateral sclerosis. J Neurol 1999; 246(Suppl 3):III22-26.
87. Stefan K, Kunesch E, Benecke R, et al. Effects of riluzole on cortical excitability in patients with amyotrophic lateral sclerosis. Ann Neurol 2001; 49: 536-9.
88. Blair IP, Williams KL, Warraich ST, et al. FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. J Neurol Neurosurg Psychiatry 2010; 81: 1286-8.
89. Nihei K, McKee AC, Kowall NW. Patterns of neuronal degeneration in the motor cortex of amyotrophic lateral sclerosis patients. Acta Neuropathologica 1993; 86: 55-64. (Pubitemid 23249074)
90. Vucic S, Cheah BC, Kiernan MC. Defining the mechanisms that underlie cortical hyperexcitability in amyotrophic lateral sclerosis. Exp Neurol 2009; 220: 177-82.
91. Eisen A, Nakajima M, Weber M. Electrophysiological studies of the corticomotoneuron in ALS. Rinsho Shinkeigaku -Clinical Neurology 1999; 39: 99.
92. Mills KR. Motor neuron disease. Studies of the corticospinal excitation of single motor neurons by magnetic brain stimulation. Brain 1995; 118: 971-82.
93. Eisen A, Nakajima M, Weber M. Corticomotorneuronal hyper-excitability in amyotrophic lateral sclerosis. J Neurol Sci 1998; 160(Suppl 1):S64-68. (Pubitemid 28522521)
94. Weber M, Eisen A. Assessment of upper and lower motor neurons in Kennedy's disease: implications for corticomotoneuronal PSTH studies. Muscle Nerve 1999; 22: 299-306. (Pubitemid 29116183)
95. Magistris MR, Rosler KM, Truffert A, et al. A clinical study of motor evoked potentials using a triple stimulation technique. Brain 1999; 122: 265-79. (Pubitemid 29067209)
96. Magistris MR, Rosler KM, Truffert A, et al. Transcranial stimulation excites virtually all motor neurons supplying the target muscle. A demonstration and a method improving the study of motor evoked potentials. Brain 1998; 121: 437-50. (Pubitemid 28116341)
97. Kleine BU, Schelhaas HJ, van Elswijk G, et al. Prospective, blind study of the triple stimulation technique in the diagnosis of ALS. Amyotroph Lateral Scler 2010; 11: 67-75.
98. Attarian S, Vedel JP, Pouget J, et al. Cortical versus spinal dysfunction in amyotrophic lateral sclerosis. Muscle Nerve 2006; 33: 677-90.
99. Pachatz C, Terracciano C, Desiato MT, et al. Upper motor neuron involvement in X-linked recessive bulbospinal muscular atrophy. Clin Neurophysiol 2007; 118: 262-8. (Pubitemid 46038810)
100. Vucic S, Kiernan M. Clarifying variability of corticomotoneuronal function in Kennedy's disease. Muscle Nerve 2011; 44: 197-201.
101. Kim W-K, Liu X, Sandner J, et al. Study of 962 patients indicates progressive muscular atrophy is a form of ALS. Neurology 2009; 73: 1686-92.
102. Geser F, Stein B, Partain M, et al. Motor neuron disease clinically limited to the lower motor neuron is a diffuse TDP-43 proteinopathy. Acta Neuropathologica 2011; 121: 509-17.
103. Ince PG, Evans J, Knopp M, et al. Corticospinal tract degeneration in the progressive muscular atrophy variant of ALS. Neurology 2003; 60: 1252-8. (Pubitemid 36460979)
104. Fisher KM, Zaaimi B, Williams TL, et al. Beta-band intermuscular coherence: a novel biomarker of upper motor neuron dysfunction in motor neuron disease. Brain 2012; 135: 2849-64.
105. Miscio G, Gukov B, Pisano F, et al. The cortico-diaphragmatic pathway involvement in amyotrophic lateral sclerosis: neurophysiological, respiratory and clinical considerations. J Neurol Sci 2006; 251: 10-6. (Pubitemid 44803037)
106. Similowski T, Attali V, Bensimon G, et al. Diaphragmatic dysfunction and dyspnoea in amyotrophic lateral sclerosis. Eur Respir J 2000; 15: 332-7. (Pubitemid 30085962)
107. Urban PP, Vogt T, Hopf HC. Corticobulbar tract involvement in amyotrophic lateral sclerosis. A transcranial magnetic stimulation study. Brain 1998; 121: 1099-108. (Pubitemid 28256983)
108. Mitsumoto H, Ulug AM, Pullman SL, et al. Quantitative objective markers for upper and lower motor neuron dysfunction in ALS. Neurology 2007; 68: 1402-10. (Pubitemid 46659092)
109. Kaufmann P, Pullman SL, Shungu DC, et al. Objective tests for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS). Neurology 2004; 62: 1753-7. (Pubitemid 38661730)
110. Turner MR, Kiernan MC, Leigh PN, et al. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol 2009; 8: 94-109.
111. Floyd AG, Yu QP, Piboolnurak P, et al. Transcranial magnetic stimulation in ALS: utility of central motor conduction tests. Neurology 2009; 72: 498-504.
112. Vucic S, Kiernan M. Pathophysiology of degeneration in familial amyotrophic lateral sclerosis. Curr Mol Med 2009; 9: 255-72.
113. Eisen A, Kim S, Pant B. Amyotrophic lateral sclerosis (ALS): a phylogenetic disease of the corticomotoneuron? Muscle Nerve 1992; 15: 219-24.
114. Desiato M, Bernardi G, Hagi AH, et al. Transcranial magnetic stimulation of motor pathways directed to muscles supplied by cranial nerves in ALS. Clin Neurophysiol 2002; 113: 132-40. (Pubitemid 34093866)
115. Eisen A, Pant B, Stewart H. Cortical excitability in amyotrophic lateral sclerosis: a clue to pathogenesis. Can J Neurol Sci 1993; 20: 11-6. (Pubitemid 23056940)
116. Browne SE, Yang L, DiMauro JP, et al. Bioenergetic abnormalities in discrete cerebral motor pathways presage spinal cord pathology in the G93A SOD1 mouse model of ALS. Neurobiol Dis 2006; 22: 599-610. (Pubitemid 43832131)
117. Nihei K, McKee AC, Kowall NW. Patterns of neuronal degeneration in the motor cortex of amyotrophic lateral sclerosis patients. Acta Neuropathologica 1993; 86: 55-64. (Pubitemid 23249074)
118. Lillo P, Hodges JR. Frontotemporal dementia and motor neurone disease: overlapping clinic-pathological disorders. J Clin Neurosci 2009; 16: 1131-5.
119. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Science 2006; 314: 130-3. (Pubitemid 44547757)
120. Renton Alan E, Majounie E, Waite A, et al. A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. Neuron 2011; 72: 257-68.
121. DeJesus-Hernandez M, Mackenzie Ian R, Boeve Bradley F, et al. Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. Neuron 2011; 72: 245-56.
122. Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem and Biophy Res Commun 2006; 351: 602-11. (Pubitemid 44708852)
123. Tsuji H, Arai T, Kametani F, et al. Molecular analysis and biochemical classification of TDP-43 proteinopathy. Brain 2012; 135: 3380-91.
124. Boillee S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006; 52: 39-59. (Pubitemid 44466358)
125. Ionov ID. Survey of ALS-associated factors potentially promoting Ca(2+) overload of motor neurons. Amyotroph Lateral Scler 2007; 8: 260-5. (Pubitemid 47543089)
126. Rothstein JD, Jin L, Dykes-Hoberg M, et al. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci U S A 1993; 90: 6591-5. (Pubitemid 23207259)
127. Rothstein JD, Van Kammen M, Levey AI, et al. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995; 38: 73-84.
128. Trotti D, Rolfs A, Danbolt NC, et al. SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. Nat Neurosci 1999; 2: 848. (Pubitemid 30491181)
129. Boston-Howes W, Gibb SL, Williams EO, et al. Caspase-3 cleaves and inactivates the glutamate transporter EAAT2. J Biol Chem 2006; 281: 14076-84. (Pubitemid 43848334)
130. Gibb SL, Boston-Howes W, Lavina ZS, et al. A Caspase-3-cleaved Fragment of the Glial Glutamate Transporter EAAT2 Is Sumoylated and Targeted to Promyelocytic Leukemia Nuclear Bodies in Mutant SOD1-linked Amyotrophic Lateral Sclerosis. J Biol Chem 2007; 282: 32480-90. (Pubitemid 350106448)
131. Haidet-Phillips AM, Hester ME, Miranda CJ, et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotech 2011; 29: 824-8.
132. Simeone TA, Sanchez RM, Rho JM. Molecular biology and ontogeny of glutamate receptors in the mammalian central nervous system. J Child Neurol 2004; 19: 343-60. (Pubitemid 38867946)
133. Kawahara Y, Ito K, Sun H, et al. Glutamate receptors: RNA editing and death of motor neurons. Nature 2004; 427: 801.
134. Kwak S, Kawahara Y. Deficient RNA editing of GluR2 and neuronal death in amyotropic lateral sclerosis. J Mol Med 2005; 83: 110-20. (Pubitemid 40379299)
135. Takuma H, Kwak S, Yoshizawa T, et al. Reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis. Ann Neurol 1999; 46: 806-15.
136. Van Damme P, Braeken D, Callewaert G, et al. GluR2 deficiency accelerates motor neuron degeneration in a mouse model of amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2005; 64: 605-12. (Pubitemid 40995275)
137. Van Damme P, Van Den Bosch L, Van Houtte E, et al. GluR2-dependent properties of AMPA receptors determine the selective vulnerability of motor neurons to excitotoxicity. J Neurophysiol 2002; 88: 1279-87. (Pubitemid 35025382)
138. Williams TL, Day NC, Ince PG, et al. Calcium-permeable alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors: a molecular determinant of selective vulnerability in amyotrophic lateral sclerosis. Ann Neurol 1997; 42: 200-7. (Pubitemid 27340465)
139. Bensimon G, Lacomblez L, Meininger V, ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994; 330: 585-91. (Pubitemid 24065791)
140. Gurney ME, Cutting FB, Zhai P, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996; 39: 147-57. (Pubitemid 26071564)
141. Gurney ME, Fleck TJ, Himes CS, et al. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology 1998; 50: 62-6. (Pubitemid 28106020)
142. Lacomblez L, Bensimon G, Leigh PN, et al. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996; 347: 1425-31. (Pubitemid 26161204)
143. Alexianu ME, Ho BK, Mohamed AH, et al. The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. Ann Neurol 1994; 36: 846-58. (Pubitemid 24370923)
144. Ince P, Stout N, Shaw P, et al. Parvalbumin and calbindin D-28k in the human motor system and in motor neuron disease. Neuropathol Appl Neurobiol 1993; 19: 291-9. (Pubitemid 23237479)
145. Choe CU, Ehrlich BE. The inositol 1,4,5-trisphosphate receptor (IP3R) and its regulators: sometimes good and sometimes bad teamwork. Sci STKE 2006; 2006:re15.
146. van Es MA, Van Vught PW, Blauw HM, et al. ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study. Lancet Neurol 2007; 6: 869-77. (Pubitemid 47407791)
147. Choi DW. Ionic dependence of glutamate neurotoxicity. J Neurosci 1987; 7: 369-79. (Pubitemid 17017466)
148. Miller RJ, Murphy SN, Glaum SR. Neuronal Ca2+ channels and their regulation by excitatory amino acids. Ann N Y Acad Sci 1989; 568: 149-58. (Pubitemid 20166530)
149. Meldrum B, Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 1990; 11: 379-87. (Pubitemid 20262465)
150. Regan RF, Panter SS, Witz A, et al. Ultrastructure of excitotoxic neuronal death in murine cortical culture. Brain Res 1995; 705: 188-98. (Pubitemid 26037364)
151. Shaw P, Kuncl WR. Current concepts in the pathogenesis of ALS. In: WR K. ed. Motor neuron disease. Lodon: WB Saunders, 2002: 37-73.
152. Bondy SC, Lee DK. Oxidative stress induced by glutamate receptor agonists. Brain Res 1993; 610: 229-33. (Pubitemid 23154795)
153. Lees GJ. Contributory mechanisms in the causation of neurodegenerative disorders. Neuroscience 1993; 54: 287-322. (Pubitemid 23153743)
154. Maher P, Davis JB. The role of monoamine metabolism in oxidative glutamate toxicity. J Neurosci 1996; 16: 6394-401. (Pubitemid 26337363)
155. de Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol 2008; 119: 497-503.
156. de Carvalho M, Naka D, Mills KR, et al. Pathophysiological significance of fasciculations in the early diagnosis of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1(Suppl 1):S43-6.
157. Kleine BU, Stegeman DF, Schelhaas HJ, et al. Firing pattern of fasciculations in ALS: evidence for axonal and neuronal origin. Neurology 2008; 70: 353-9. (Pubitemid 351653397)
158. Mills KR. Characteristics of fasciculations in amyotrophic lateral sclerosis and the benign fasciculation syndrome. Brain 2010; 133: 3458-69.
159. Bostock H, Sharief MK, Reid G, et al. Axonal ion channel dysfunction in amyotrophic lateral sclerosis. Brain 1995; 118: 217-25.
160. Kanai K, Kuwabara S, Misawa S, et al. Altered axonal excitability properties in amyotrophic lateral sclerosis: impaired potassium channel function related to disease stage. Brain 2006; 129: 953-62.
161. Kanai K, Shibuya K, Sato Y, et al. Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2012; 83: 734-8.
162. Vucic S, Kiernan MC. Axonal excitability properties in amyotrophic lateral sclerosis. Clin Neurophysiol 2006; 117: 1458-66. (Pubitemid 43947716)
163. Boillee S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006; 52: 39-59. (Pubitemid 44466358)
164. Chung MJ, Suh YL. Ultrastructural changes of mitochondria in the skeletal muscle of patients with amyotrophic lateral sclerosis. Ultrastruct Pathol 2002; 26: 3-7.
165. Higgins CM, Jung C, Xu Z. ALS-associated mutant SOD1G93A causes mitochondrial vacuolation by expansion of the intermembrane space and by involvement of SOD1 aggregation and peroxisomes. BMC Neurosci 2003; 4: 16.
166. Kirkinezos IG, Bacman SR, Hernandez D, et al. Cytochrome c association with the inner mitochondrial membrane is impaired in the CNS of G93A-SOD1 mice. J Neurosci 2005; 25: 164-72. (Pubitemid 40110777)
167. Lederer CW, Torrisi A, Pantelidou M, et al. Pathways and genes differentially expressed in the motor cortex of patients with sporadic amyotrophic lateral sclerosis. BMC Genomics 2007; 8: 26.
168. Xu Z, Jung C, Higgins C, et al. Mitochondrial degeneration in amyotrophic lateral sclerosis. J Bioenerg Biomembr 2004; 36: 395-9. (Pubitemid 39619847)
169. Dugan LL, Choi DW. Excitotoxicity, free radicals, and cell membrane changes. Ann Neurol 1994; 35:S17-21. (Pubitemid 24153859)
170. Heath PR, Tomkins J, Ince PG, et al. Quantitative assessment of AMPA receptor mRNA in human spinal motor neurons isolated by laser capture microdissection. Neuroreport 2002; 13: 1753-7. (Pubitemid 35333155)
171. Cheah BC, Kiernan MC. Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis. IDrugs 2010; 13: 911-20.
172. Cudkowicz M, Bozik ME, Ingersoll EW, et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med 2011; 17: 1652-6.
173. Chou SM, Norris FH. Amyotrophic lateral sclerosis: lower motor neuron disease spreading to upper motor neurons. Muscle Nerve 1993; 16: 864-9. (Pubitemid 23209146)
174. Gould TW, Buss RR, Vinsant S, et al. Complete dissociation of motor neuron death from motor dysfunction by Bax deletion in a mouse model of ALS. J Neurosci 2006; 26: 8774-86. (Pubitemid 44319413)
175. Pagani MR, Reisin RC, Uchitel OD. Calcium signaling pathways mediating synaptic potentiation triggered by amyotrophic lateral sclerosis IgG in motor nerve terminals. J Neurosci 2006; 26: 2661-72. (Pubitemid 43357849)
176. Pun S, Santos AF, Saxena S, et al. Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat Neurosci 2006; 9: 408-19. (Pubitemid 43290971)
177. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009; 73: 1227-33.
178. Gowers WR. A Manual of Diseases of the Nervous System: spinal cord and nerves. In. London: Churchill, 1888: 356-381.
179. Kiernan J, Hudson A. Changes in sizes of cortical and lower motor neurons in amyotrophic lateral sclerosis. Brain 1991: 843-53.
180. Pamphlett R, Kril J, Hng T. Motor neuron disease: a primary disorder of corticomotoneurons? Muscle Nerve 1995: 314-18.
181. Flament D, Goldsmith P, Buckley CJ, et al. Task dependence of responses in first dorsal interosseous muscle to magnetic brain stimulation in man. J Physiol 1993; 464: 361-78. (Pubitemid 23169320)
182. Kanouchi T, Ohkubo T, Yokota T. Can regional spreading of amyotrophic lateral sclerosis motor symptoms be explained by prion-like propagation? J Neurol Neurosurg Psychiatry 2012; 83: 739-45.
183. Fujimura-Kiyono C, Kimura F, Ishida S, et al. Onset and spreading patterns of lower motor neuron involvements predict survival in sporadic amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2011; 82: 1244-9.
184. King OD, Gitler AD, Shorter J. The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res 2012; 1462: 61-80.
185. de Carvalho M. Testing upper motor neuron function in amyotrophic lateral sclerosis: the most difficult task of neurophysiology. Brain 2012; 135: 2581-2.
186. Costa J, Swash M, de Carvalho M. Awaji criteria for the diagnosis of amyotrophic lateral sclerosis: a systematic review. Arch Neurol 2012: 1-7.
187. Udaka F, Sawada H, Seriu N, et al. MRI and SPECT findings in amyotrophic lateral sclerosis. Demonstration of upper motor neurone involvement by clinical neuroimaging. Neuroradiology 1992; 34: 389-93.
188. Ellis CM, Simmonds A, Jones D, et al. Diffusion tensor MRI assesses corticospinal tract damage in ALS. Neurology 1999; 53: 1051-8. (Pubitemid 29442122)
189. Ellis CM, Simmons A, Andrews C, et al. A proton magnetic resonance spectroscopic study in ALS: correlation with clinical findings. Neurology 1998; 51: 1104-9. (Pubitemid 28473408)
190. Foerster BR, Dwamena BA, Petrou M, et al. Diagnostic accuracy using diffusion tensor imaging in the diagnosis of ALS: a meta-analysis. Acad Radiol 2012; 19: 1075-86.
191. Verstraete E, Veldink JH, Hendrikse J, et al. Structural MRI reveals cortical thinning in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2012; 83: 383-8.
192. Cosottini M, Pesaresi I, Piazza S, et al. Structural and functional evaluation of cortical motor areas in Amyotrophic Lateral Sclerosis. Exp Neurol 2012; 234: 169-80.
193. Rose S, Pannek K, Bell C, et al. Direct evidence of intra- and interhemispheric corticomotor network degeneration in amyotrophic lateral sclerosis: an automated MRI structural connectivity study. NeuroImage 2012; 59: 2661-9.
194. Turner MR, Hammers A, Al-Chalabi A, et al. Distinct cerebral lesions in sporadic and 'D90A' SOD1 ALS: studies with [11C]flumazenil PET. Brain 2005; 128: 1323-9. (Pubitemid 40826186)
195. Turner MR, Rabiner EA, Hammers A, et al. [11C]-WAY100635 PET demonstrates marked 5-HT1A receptor changes in sporadic ALS. Brain 2005; 128: 896-905. (Pubitemid 40516926)
196. Tsujimoto M, Senda J, Ishihara T, et al. Behavioral changes in early ALS correlate with voxel-based morphometry and diffusion tensor imaging. J Neurol Sci 2011; 307: 34-40.
197. Turner MR, Grosskreutz J, Kassubek J, et al. Towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurol 2011; 10: 400-3.
198. Turner MR, Modo M. Advances in the application of MRI to amyotrophic lateral sclerosis. Expert Opin Med Diagn 2010; 4: 483-96.